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Abstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest 
the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical 
cosmetic procedures in the United States. There has been research spanning over two decades 
dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are 
now two Food and Drug Administration (FDA) approved botulinum toxin type A options in the 
United States: Botox® and Dysport™, with new advances being made in the field.
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Introduction
There is an increasing demand for a reversal of the aging process and recently more 
people are turning to minimally-invasive methods to meet this goal, in lieu of surgery. 
Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic 
procedures in the United States, with 4.6 million procedures in 2007.1 Glabellar 
lines occur naturally with facial animation, a continuous practice that facilitates 
 communication. Contraction of the procerus and corrugator supercilli muscles produces 
creasing of the glabellar skin and ultimately permanent rhytids develop. Administration 
of low doses of botulinum toxin type A into bilateral corrugator supercilii and procerus 
muscles paralyze muscular activity, thus diminishing the appearance of dynamic rhytids 
of the glabella. Botulinum toxin injection is a minimally invasive procedure with 
relatively quick onset of action seen within three days to two weeks of administration. 
The effects of botulinum toxin type A commonly last for three to six months, although 
there is a report of duration as long as twelve months.2 Botulinum toxin type A is a 
successful treatment clinically, but more importantly patient satisfaction is consistently 
high with its use.3 The purpose of this review is to discuss the important topics sur-
rounding and pertaining to the role of botulinum toxin type A in the management of 
glabellar rhytids, as well as, to compare and contrast the FDA approved commercial 
botulinum toxin type A products.
Botulinum toxin is a neurotoxic protein produced by Clostridium botulinum, a 
Gram-negative anaerobic bacterium. In the 1980’s, Dr Alan Scott was the first to utilize 
botulinum toxin clinically with his research on strabismus and blepharospasm, after 
using it successfully in experiments using monkeys in the 1970’s. Now botulinum toxin 
is used to treat many medical conditions including cervical dystonia, hyperhidrosis, 
strabismus, and blepharospasm. The first study4 indicating the utility of botulinum toxin 
type A for the treatment of hyperfunctional facial lines occurred in the early 1990’s.
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in the appearance of moderate to severe glabellar lines in 
adults aged 65 or younger. It was just several months ago 
that Dysport™ gained FDA approval for cosmetic indications 
although it has been used widely in Europe for several years. 
The list of ingredients for each of these products is listed in 
Table 1. Two other botulinum toxin type A products are avail-
able outside the United States for treatment of blepharospasm 
and torticollis: Xeomin® (Mertz, Frankfurt, Germany) and 
Neuronox® (Medy-Tox Inc., South Korea).
Botox®, Dysport™, and any other botulinum toxin type A 
products are distinctive and not interchangeable. Thus, the 
generic term, botulinum toxin type A, will be used when 
a distinction does not need to be made, but otherwise the 
 specific product will be named throughout the review.
Safety and efficacy  
of botulinum toxin type A
The safety and efficacy of botulinum toxin type A has 
been investigated in both small, single-center trials,4–12 
Normal facial muscle cell contraction occurs when 
 acetylcholine released from the nerve terminal, diffuses 
across the synaptic cleft, and attaches to its receptor on the 
muscle cell (Figure 1a). After injection of botulinum toxin 
type A into the muscle, the neurotoxin is taken up by the adja-
cent nerve terminal. Within the terminal it prevents proper 
binding of the synaptic vesicle containing acetylcholine. The 
neurotoxin accomplishes this by cleaving SNAP-25, a protein 
that is crucial for docking of the vesicle to the nerve end-
ing. Thus, neurotransmitter release into the synaptic cleft is 
inhibited and muscle contraction cannot occur (Figure 1b).
There are several botulinum toxin type A products available 
worldwide. In North America, onabotulinumtoxinA, known as 
Botox® (Allergan, Inc., Irvine, CA, USA) and abobotulinum-
toxinA, known as Dysport™ (Ipsen Ltd, Wrexham, UK and 
Medicis Aesthetics Inc., Scottsdale, AZ) are FDA approved 
products for aesthetic treatments. Botox® was approved in 1989 
for certain medical conditions, but it was not until 2002 that this 
product received FDA approval for temporary improvement 
Muscle cell contracts
Axon terminal
Acetylcholine
Synaptic vesicle 
Syntaxin
SNAP 25 
Synaptobrevin
Figure 1a Normal neurotransmitter release.
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Figure 1b Mechanism of action of botulinum toxin type A.
as well as, large, multicenter, randomized, double-blind 
studies.13–17 Recently, several trials have addressed the 
concern of long-term safety and efficacy of botulinum toxin 
type A and these found sustained safety and efficacy after 
repeated administration of the neurotoxin.15,18–23 There is 
unequivocal evidence from two decades of research that 
botulinum toxin type A is safe and effective for the treat-
ment of glabellar lines.
Two interesting clinical pearls have been discovered 
 during the course of the research trials. First, while the data 
is limited and not statistically significant, it appears that 
there is a significant decrease in efficacy seen in subjects 
older than 65 years of age.16,24,25 Second, Carruthers et al 
found that the effects on patient appearance at rest appear to 
be sustained longer than the effect at maximal frown, thus 
suggesting that botulinum toxin type A may have a persistent 
benefit even once the paralysis has reversed. The authors 
hypothesize that this may occur for several reasons including 
dermal remodeling, slight muscle atrophy, and behavior 
 modification.13–14
Dosing
Many different doses have been evaluated for the treatment 
of glabellar rhytids, although the current suggested dose is 
20 Units (U) for Botox®24 and 50 U for Dysport™25,26 It is 
recommended that there should be at least a three month 
period between botulinum toxin injections. Carruthers 
et al compared 10, 20, 30, and 40 U doses of Botox® for 
the improvement in glabellar rhytids in females and found 
that dosing with 20–40 U of botulinum toxin type A was 
significantly more effective at reducing glabellar lines than 
10 U alone.2 A study evaluating 20 U compared to 30 U in 
African American females found that either dose was safe 
and effective.27 Larger doses of botulinum toxin type A are 
needed to improve the glabellar rhytids in men. In one dose-
comparing study, it was shown that 20 U of Botox® was 
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ineffective and greater treatment outcomes were seen with 
the use of 40, 60, and 80 U doses.28
In June of 2009, Carruthers et al published a dose-comparing 
study with Botox® for the improvement in upper facial rhytids 
(crows feet, forehead, and glabella) and found similar efficacy 
and safety with 32, 64, and 96 U. Due to the dose-dependent 
response observed and a higher incidence of brow ptosis 
with 96 U, the authors concluded it is best to use a more 
moderate 64 U.29
There is less published literature evaluating dosing for 
Dysport™. After a Phase II dose-ranging trial,26 most subse-
quent trials evaluated a 50 U dose compared to placebo and 
found it to be safe and effective.15,17 Another dose-ranging 
trial comparing 20, 50, 75 U, or placebo found 50 U of 
Dysport™ to be the optimal dose.30 Comparatively, another 
trial found that both 30 U and 50 U were safe and effec-
tive, although there was a slight improvement in treatment 
outcomes with the 50 U dose.31 Kane et al propose that a 
standardized dose is not optimal since gender and muscle 
mass affect the dose required for efficacy.16 This group car-
ried out a randomized, double-blind, placebo-controlled trial 
that evaluated variable doses of Dysport™ based on gender 
and muscle mass. After grading the mass of the procerus and 
corrugator muscles (small, medium, large) the investigators 
established the dosing for each subject with options includ-
ing; 50, 60, or 70 U in women and 60, 70, or 80 U in men. 
The investigators found the variable doses to be efficacious 
compared to placebo and did not report an increase in adverse 
events in the higher treatment doses.
As mentioned, Botox®, Dysport™, and any other 
 botulinum toxin type A product have different potencies 
and the doses are not interchangeable. The biologic activity 
of the toxin is measured in mouse units (LD
50
), the median 
intraperitoneal lethal dose in mice. Despite the fact that 
both neurotoxins are supplied in units of biologic activity 
(LD
50
), the units are not transposable due to differences in 
assays used to determine the units. There have been a few 
studies attempting to create dose ratios between Botox® and 
 Dysport™ to compare efficacy. Lowe et al found 2.5:1 dose 
ratio (Dysport™: Botox®) to be comparable in terms of toler-
ability. The authors reported prolonged efficacy and higher 
patient satisfaction in the Botox® treatment arm at the week 12 
timepoint.32 Others suggest that at 4:1 dose ratio (Dysport™:
Botox®) provides similar clinical efficacy.33,34 Wohlfarth et al 
recently carried out a systematic review of preclinical and 
clinical dose ratio studies of botulinum toxin type A used for 
various therapeutic indications. The authors found a range 
of Dysport™: Botox® ratios from 2:1 to 11:1 described in the 
literature. Their literature review established that random-
ized, controlled clinical trials indicate that a 3:1 dose ratio 
is more appropriate than 4:1, and there is no evidence for a 
ratio greater than 4:1. However, the studies do not prove that 
a 3:1 dose ratio is equivalent clinically.35 A previous study 
by Wohlfarth et al used statistical modeling with compound 
muscle action potential amplitude of the extensor digitorum 
brevis to confirm the use of a 3:1 dose ratio.36
Dilution
There is disagreement over the effect of dilution volume on 
treatment efficacy and there is limited clinical trial data to 
support either argument. Dilutions range between 100 U/cc 
to 10 U/cc, with most choosing to dilute 100 U of botulinum 
toxin with 1–3 cc of saline. Using a more concentrated solu-
tion, such as 1 U/0.1 cc, may allow for more accurate place-
ment, limit pain, restrict diffusion, and thus decrease risk of 
side effects. Administering less concentrated doses, such as 
4 U/1cc, may be easier to work with. The increased potential 
for diffusion with lower concentration, higher volume doses 
can be advantageous since it allows fewer units to cover a 
greater area. Dilution may just be a matter of preference, as 
one comparative study for the treatment of blepharospasm 
showed no difference in efficacy or incidence of patient-
reported complications (eg, bruising, redness, complications 
of injection) with two different dilutions (10 U/cc vs. 100 U/cc) 
injected into either ocular area.37 Similarly, other studies 
found that concentrations varying from 10 to 100 U/cc had 
no difference in efficacy and the adverse events experienced 
were similar across all dilution arms. The more dilute treat-
ment arms did have more subjects with swelling and ptosis 
Table I List of ingredients for Botox® and Dysport™
Product Active ingredients Inactive ingredients
BOTOX® 
(onabotulinumtoxinA)
50 Units of  
botulinum toxin 
type A
0.25 mg of human 
albumin
0.45 mg of sodium 
chloride
100 Units of  
botulinum toxin  
type A
0.5 mg of human 
albumin
0.9 mg of sodium 
chloride
DYSPORT™
(abobotulinumtoxinA)
300 Units of  
botulinum toxin  
type A
125 mcg of human 
albumin 
2.5 mg of lactose
500 Units of  
botulinum toxin  
type A
125 mcg of human 
albumin
2.5 mg of lactose
Note: Each product is supplied in multiple unit vials.
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although the data was not statistically significant.38,39 Hankins 
et al found no difference in efficacy or adverse events in con-
centrations ranging from 50 to 200 U/cc.7 However, a study 
conducted by Hsu et al determined that dilution did impact 
treatment efficacy, as the larger volume injections led to 
greater diffusion and increased the area affected.40
With the more concentrated dilutions, it is efficient to 
inject with a 30-gauge needle and a 0.3 cc insulin syringe. 
The insulin syringe does not have a dead space within the 
needle hub and this serves to decrease the waste of botulinum 
toxin within the needle. With more dilute concentrations, it 
is best to use a traditional 30–32 gauge needle.
Diffusion
With injections into the small targets of the glabella and 
knowledge of the delicate surrounding areas, there is concern 
of product diffusion leading to muscle paralysis outside of the 
target site. There is debate about the mechanism of diffusion, 
as well as, how and if diffusion differs among botulinum 
toxin type A products.
Some believe the complex size of the botulinum toxin 
affects the diffusion potential and that larger proteins have 
less diffusion potential. If this is the case, Botox® (uniform 
900 kDa complexes) would be less likely to diffuse outside 
the target tissue compared to Dysport™ (heterogeneous 
mixture of 500–900 kDa complexes). The molecular weight 
of each product is reported and refuted in the literature and 
hence the validity of this data is debatable.41
There are several studies that have found no significant 
difference in diffusion between Botox® and Dysport™.36,42,43 
Furthermore, investigators suggest the complex protein size 
is irrelevant since dissociation of the complex occurs immedi-
ately after injection, releasing uniform-sized botulinum toxin. 
These researchers believe diffusion simply depends on the 
concentration and volume of product used. In other words, 
the higher the concentration and the greater the volume, the 
greater the diffusion potential.36,41
Reconstitution and storage
Previously, it was thought that botulinum toxin should be 
used within 4 hours of reconstitution.44 The Botox® pack-
age insert instructs to use the product within 24 hours of 
reconstitution,24 while the Dysport™ package insert instructs 
use within 4 hours.25 The concern is decreased efficacy 
and increased bacterial growth the longer the reconstituted 
neurotoxin remains unused. Many different studies have 
evaluated longer reconstitution periods including 15 days, 
42 days, and 49 days without lessening efficacy or producing 
evidence of bacterial contamination.45–47 Both preservative-
free and preserved saline were used in these studies and both 
were shown to be safe after prolonged reconstitution. Once 
reconstituted, botulinum toxin must be kept at a refrigerated 
temperature between 2–8°C.
Complications
The most common side effects reported with botulinum 
toxin type A injections include pain, swelling, erythema, 
ecchymosis, respiratory infection, headache, nasopharyngitis, 
sinusitis, flu-like symptoms, nausea, and limited hypesthesia. 
In clinical trials with Botox®, the incidence of headache, 
nausea, and flu-like symptoms in the treatment arm was the 
same as seen in the placebo arm.13,14,24
Upper eyelid ptosis is also a complication in treatment of 
the glabellar region. Understanding anatomic landmarks and 
proper technique will decrease the incidence of ptosis. This 
complication arises when the neurotoxin diffuses through the 
orbital septum and affects the levator palpebrae superioris 
muscle. The rate of ptosis appears to be determined by the 
skill and experience of the injector. In studies with repeated 
administration of botulinum toxin type A, the rate of ptosis 
decreased over successive cycles indicating improved technique 
with experience.18 Reported rates of ptosis from large clinical 
trials are similar between Botox® and Dysport™ and range from 
0.8% to 5.4%.13–15,17–19,26 Ptosis can be treated with α-adrenergic 
agonist (apraclonidine 0.5% or phenylephrine hydrochloride 
2.5%) ophthalmic drops twice a day to the affected side.48
The complications associated with botulinum toxin injection 
are most often mild and self-limited. Most complications are 
related to technique, hence complications decrease with proper 
training of facial anatomy, dosing, and injection technique.
Administration technique
Proper technique for injection of the glabella is debatable, but 
variations of procedure will still lead to successful treatment 
outcomes. The patient should be seated in the upright position 
and all injections should be aimed away from the eye. The 
neurotoxin should be injected into the muscle belly of the 
procerus and corrugator supercilli muscles. Administration 
of the neurotoxin into the forehead should be superficial, 
aiming for the subcutis. The neurotoxin will spread down 
to the frontalis muscle. The toxin may spread up to 3 cm 
from the injection site and this should be considered during 
administration. There is increased likelihood of eyelid ptosis 
if the toxin is injected too inferior on the forehead. Medial 
corrugator injections should be placed 1 cm above the bony 
supraorbital ridge to avoid ptosis.
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Massage after injection is another debated practice among 
physicians. Massaging horizontally may facilitate smoothing 
of the lump after injection, aid with diffusion, and prevent 
inferior spread of the botulinum toxin.48 Massage becomes 
problematic, however, if the botulinum toxin diffuses to other 
muscles. There are currently no studies to support either argu-
ment. Digital pressure after the injection may also decrease 
the diffusion of the toxin.48 After the treatment, patients may 
be instructed to stay upright for at least 4 hours to prevent the 
diffusion of the product in the wrong direction, although there 
is no data to confirm the necessity of this action. Some phy-
sicians also instruct patients to contract the treated muscles 
for the first couple hours to distribute the toxin to the entire 
muscle, but, again, this may be unnecessary.
Several of the complications discussed above can 
potentially be prevented. For instance, to prevent inducing 
ecchymosis with superficial injection the patient should be 
advised to avoid aspirin, nonsteroidal anti-inflammatory 
drugs (NSAIDS), and high-dose vitamin E49 for at least a 
week prior to injection. Likewise, removing makeup prior 
to injection will allow for better visualization of the treat-
ment area and avoidance of small, superficial vessels.50 It has 
been deemed helpful to hold direct pressure and application 
of ice to the injection site.48,50 To decrease the amount of 
discomfort for the patient, use of a topical lidocaine prior 
to the procedure, and slow injection with small amounts of 
concentrated botulinum toxin type A using a 30–34 gauge 
needle is recommended.48,51,52
Furthermore, it has been found that patients complain 
of less pain when the botulinum toxin is reconstituted with 
preserved saline, rather than sterile, non-preserved saline as 
directed on the package insert since the preservative in the 
saline, benzyl alcohol, acts as an anesthetic. This is supported 
by a finding in a randomized clinical trial where not only 
did the subjects report less pain with botulinum toxin type 
A reconstituted with preserved saline, but it was found to be 
as safe and effective as that reconstituted with non-preserved 
saline.52 With preserved saline, there does not appear to be 
an increased risk of bacterial contamination after prolonged 
reconstitution and repeated extractions from the bottle.53 Pre-
paring patients for the possibility of headache after injection 
and instruction to use over the counter (OTC) analgesics can 
prevent unnecessary patient panic and worry.
Contraindications to use
There are several contraindications for the use of botulinum 
toxin type A, including active infection at the injection site 
or history of a hypersensitivity reaction to any of the ingre-
dients (ie, human albumin, lactose, saline, botulinum toxin 
type A). Dysport™ may contain trace amounts of cow’s milk 
protein and patients known to be allergic to this should not 
be treated with Dysport™. However, it is safe for patients 
with lactose intolerance to receive Dysport™. Low doses of 
botulinum toxin may induce a neuromuscular crisis. Patients 
with a history of neuromuscular disorders including myas-
thenia gravis, Eaton–Lambert syndrome, and amyotrophic 
lateral sclerosis should not receive botulinum toxin injections. 
Patients taking aminoglycoside antibiotics including, but not 
limited to, amikacin, neomycin, streptomycin, tobramycin, or 
gentamicin should avoid botulinum toxin because this com-
bination may potentiate the effect of the neurotoxin. Patients 
should also avoid botulinum toxin injections if they are taking 
other drugs that interfere with neuromuscular transmission 
such as magnesium sulfate, succinylcholine, penicillamine, 
tetracyclines, calcium channel blockers, lincosamides, poly-
myxins, or anticholinesterases. Despite the lack of evidence 
of teratogenicity with Botox® or Dysport™, both are category 
C drugs and should not be administered during pregnancy. 
It is not known whether the neurotoxin is excreted in human 
milk and therefore should not be used in nursing patients. 
Botulinum toxin type A should not be used in subjects with 
a bleeding disorder and used with care in patients taking 
medication that affects clotting. Relative contraindications 
to use include patients with unrealistic goals and patients 
with psychiatric disease.24,25
Botulinum toxin and resistance
Botulinum toxin is a potentially immunogenic protein that can 
cause neutralizing antibody formation with repeated injections. 
Antibody formation may lead to decreased effectiveness of the 
neurotoxin. There appears to be a heightened risk of antibody 
formation with increased doses and frequency of administra-
tion. With the first generation of Botox®, it was recommended 
that injections take place at greater than 1 month intervals and 
that no more than 100 Units be used in a patient at one time. 
The protein load of the newer generation Botox® has decreased 
5-fold consequently reducing the antigenic potential.48 Several 
researchers in the fields of neurology and dermatology have 
looked into the issue of resistance and established a variety 
of findings. These findings must be evaluated while keeping 
in mind that observed incidence of antibody positivity in an 
assay may be affected by methodology and several other fac-
tors. In a four year trial for cervical dystonia, 4 of 326 (1.2%) 
subjects tested positive for antibodies. Three of these subjects 
stopped responding clinically to botulinum toxin.54 Lange 
et al55 report that while they had a large number of subjects 
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with neutralizing antibodies, many of them still responded 
clinically to treatment. Secondary non-responders with 
neutralizing antibodies were seen in higher dose indications 
(eg, focal spasticity and spasmodic torticollis) and with shorter 
injection intervals. Also, neutralizing antibody development 
was independent of the commercial preparation used.55 
Other trials within the scope of cosmetic treatments found 
no antibody formation with repeated botulinum toxin type A 
injections.15,22 It is possible that the dosage of botulinum toxin 
type A for cosmetic indications is not significant enough to 
induce antibody formation.
Evaluating treatment outcomes
In clinical trials, treatment outcomes are measured with inves-
tigator global assessments and patient satisfaction rating scales. 
These traditional global assessments do not evaluate the specific 
outcomes that are significant to patients. Outside of clinical trials 
to determine efficacy, patient reported outcomes are truly the 
most import measure of treatment success. Carruthers et al have 
proposed two new patient-reported outcome measures: the facial 
line outcome questionnaire (FLO) and the self-perception of age 
(SPA). The FLO uses scales to allow patients to rate the extent to 
which their facial lines impact their self-perceptions. The goal of 
the SPA is to assess the patient’s current perception of his or her 
age of appearance.56–58 The FLO and SPA assessments provide 
evidence that botulinum toxin type A injections are improving 
patients’ perception of themselves, which is the real determinant 
of treatment success with cosmetic procedures.59
Improving treatment outcomes
As discussed above, patient satisfaction is crucial and 
there are several ways to improve treatment outcomes 
in this area. The initial visit should consist of a detailed 
consultation discussing the goals and expectations of 
each patient. It is advisable to use a mirror to allow the 
patient to point out what they consider to be the problem 
area while gently pointing out facial asymmetry, as well. 
If the patient has grand visions, attempts should be made 
to reestablish realistic expectations prior to any cosmetic 
procedures. Providing sufficient pain management should 
not be overlooked as patients will reflect upon the entire 
process when determining treatment success. At follow-up 
it is recommended to demonstrate muscle immobility with a 
mirror and to utilize before and after photos.
In addition to determining patient-perceived efficacy, the 
FLO assessment can be used to ascertain treatment goals for 
a patient. The FLO assessment may help physicians gain a 
better understanding of a patient’s objectives for treatment 
success compared to general global assessments. The SPA 
can be used to show patients the value of treatment.57 Patient 
satisfaction appears to improve when multiple facial areas are 
treated in conjunction since this may lead to a more natural 
look.56,59 Treatments with botulinum toxin type A need to be 
customized to each individual patient depending on physi-
cian assessment of the patient’s needs and the patient’s own 
treatment expectations.
Emerging science:  Topical  
botulinum toxin and  
new injectables
There has been increasing discussion about topical prepara-
tions of botulinum toxin type A, but there is concern over 
adequate percutaneous penetration and drug delivery to the 
muscle since neurotoxin is a large molecule. Consequently, 
the appropriate vehicle will be crucial to the success of a 
topical version. A topical product would be a useful, pain-
less option, especially for treating needle-phobic patients. It 
seems unlikely that there will be as great an effect with the 
topical compared to injection treatment though.
Azzalure® (Galderma, USA) is a topical product adapted 
from Dysport® that has been approved in several European 
countries. Azzalure® is indicated for the temporary improve-
ment in the appearance of moderate to severe glabellar lines in 
adult patients under 65 years, when the severity of these lines 
has an important psychological impact on the patient.60 Revance 
Therapeutics (Newark, CA, USA) is currently conducting 
clinical trials with RT001, a botulinum toxin type A topical 
gel for the reduction of crow’s feet wrinkles.61 Phase I studies 
found RT001 to be safe and tolerable when applied to the 
forearms of 41 healthy subjects.62 Early Phase II studies found 
it was safe and effective for improvement in the appearance of 
lateral canthal lines. Adverse events experienced included mild 
skin erythema, ocular erythema, and ocular burning/stinging 
sensation.63 Currently, RT001 is in a US Phase II B clinical 
study. Chajchir et al conducted a small, single-center study 
comparing a topical botulinum toxin cream (CosmeTox) versus 
placebo cream on upper face wrinkles and found the topical 
neurotoxin to be effective in terms of subject-perception.64 In 
this study, the botulinum toxin type A was homogenized with 
a novel vehicle (InParT) which is thought to aid in appropriate 
penetration and delivery of the toxin to the muscle.65
Also in pre-clinical trials, is the next generation botulinum 
toxin type A injection, RT002 (Revance Therapeutics). The 
manufacturer hypothesizes that the botulinum toxin type 
A molecule plus the patented TransMTS™ peptide technology 
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could improve onset of action, increase duration of effect, 
and limit diffusion away from treatment site.66 Large, double-
blind, randomized clinical trials need to be carried out to 
confirm safety and efficacy in each of these new products.
Conclusion
When properly used, botulinum toxin type A is effective for 
the improvement of glabellar rhytids and with little incidence 
of complications. There are multiple botulinum toxin type A 
products that are commercially available, although only two 
are FDA approved. Each product is distinct and, as mentioned 
above, they are not interchangeable. Hence, clinical research 
must be carried out for each specific product and conclusions 
from clinical trials cannot necessarily be applied to any 
other botulinum toxin type A product. There is still room 
for growth and research to be done within the discipline of 
aesthetic use of botulinum toxin type A.
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